Oncology | Drugs in Discovery | UNITED STATES

Sana Biotechnology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

Lead Product(s): Gene and Cell therapies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: RCH Venture Partners

Deal Size: $700.0 million Upfront Cash: Undisclosed

Deal Type: Financing June 23, 2020

Details:

Proceeds from Sana’s financing will be used to advance discovery and development within the company’s core platforms, including gene delivery, immunology, stem cell biology, and gene modification and control.

Egle Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda

Lead Product(s): Tumor-infiltrating Treg

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Takeda Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 11, 2020

Details:

Under the terms of the agreement, Egle Therapeutics will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies.

Lycia Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Lycia uncloaks with $50M to Tackle Protein Degradation

Lead Product(s): Lysosome targeting chimeras

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Versant Ventures

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Financing June 09, 2020

Details:

Proceeds are being used to develop lysosomal targeting chimeras, or LYTACs, as therapeutics for a broad set of currently intractable cell surface targets.

Vividion Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Meeting

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 15, 2020

Details:

First reported E3 ligase beyond Cereblon and VHL shown to support broad targeted protein degradation of multiple targets in vivo.

Modulus Discovery

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Modulus Discovery Closes $25.5M USD Series B

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: SBI Investments

Deal Size: $25.5 million Upfront Cash: Undisclosed

Deal Type: Series B Financing May 13, 2020

Details:

Modulus will use the proceeds to further its unique small-molecule lead programs in oncology and inflammatory / immune disorders and expand its portfolio of early programs and collaborations including those with its strategic partner, PeptiDream, Inc.

Abveris

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse® on the Berkeley Lights Beacon®

Lead Product(s): Human monoclonal antibodies

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Nkarta

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Partnership May 12, 2020

Details:

Under the terms of the agreement, Abveris will apply its next-generation B cell screening platform (powered by the Berkeley Lights Beacon®) to rapidly discover fully human monoclonal antibodies using the Trianni Mouse®, an industry-leading transgenic mouse R&D platform.

Tocagen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets

Lead Product(s): Vocimagene amiretrorepvec

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: Denovo Biopharma

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition April 28, 2020

Details:

The acquisition includes Tocagen's retroviral replicating vector platform, investigational gene therapy and drug regimen for oncology: Toca 511 and Toca FC and several other development programs.

Rome Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Rome Therapeutics debuts with $50M and Rosana Kapeller as CEO

Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: ARCH Venture Partners

Deal Size: $50.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing April 27, 2020

Details:

The capital would help in clinical advancement of several promising drug targets identified by ROME and may boost launch of multiple discovery programs.

TScan Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

TScan Announces Collaboration with Novartis on the Discovery and Development of Novel T Cell Receptor Therapies

Lead Product(s): TSC-200

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Licensing Agreement April 15, 2020

Details:

Under the agreement, TScan will identify and characterize TCRs, and Novartis will have the option to license and develop TCRs for up to three novel targets.

Arrakis Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche

Lead Product(s): RNA targeted small molecule

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Small molecule

Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

Deal Size: $190.0 million Upfront Cash: $190.0 million

Deal Type: Licensing Agreement April 08, 2020

Details:

Arrakis will lead discovery and research activities for each target to a defined point, at which time Roche will have the right to exclusively pursue further preclinical and clinical development.

Find

Find Novel Oncology Drugs in Discovery in UNITED STATES

United States

Product Type

Companies

Sana Biotechnology

What’s it take to raise $700M-plus for a biotech startup? Steve Harr has some thoughts on that

Egle Therapeutics

Egle Therapeutics Enters Into a Corporate Strategic Research Alliance with Takeda

Lycia Therapeutics

Lycia uncloaks with $50M to Tackle Protein Degradation

Vividion Therapeutics

Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Meeting

Modulus Discovery

Modulus Discovery Closes $25.5M USD Series B

Abveris

Abveris Announces Human Antibody Discovery Partnership with Nkarta using the Trianni Mouse® on the Berkeley Lights Beacon®

Tocagen

Denovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related Assets

Rome Therapeutics

Rome Therapeutics debuts with $50M and Rosana Kapeller as CEO

TScan Therapeutics

TScan Announces Collaboration with Novartis on the Discovery and Development of Novel T Cell Receptor Therapies

Arrakis Therapeutics

Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche